ARC Digital Bioprocess Development Hub
@arc_digital_bioprocess_development_hub
Parkville, Victoriahttps://digitalbioprocesshub.org.au/ Pharmaceutical ManufacturingOverview
About ARC Digital Bioprocess Development Hub
The ARC Digital Bioprocess Development Hub aims to transform Australia’s biopharmaceutical manufacturing industry by increasing digital innovation, productivity and competitiveness through the development of digitally integrated advanced manufacturing processes and a platform for industry adoption. The program will address key bioprocessing research challenges and develop new process and digital models that can predict and optimise manufacturing processes, resulting in greater yields, faster and more flexible processes and enhanced product stability.
The Hub is a collaborative program of significant scope and scale funded through the Australian Research Council Industrial Transformation Research Hub scheme with contributions from all partners of more than $18 M (cash and in kind).
It draws together expertise from The University of Melbourne, University of Technology Sydney and RMIT University, together with partner organisations CSL Innovation, Pall Australia and Patheon Biologics Australia. Three Other Organisations (Yokogawa Insilico Biotechnology, Mass Dynamics and Sartorius) and three leading international universities (University of Tartu, Estonia; Utrecht University, Netherlands; The University of Nottingham, United Kingdom) are also participants of the Hub.
This forms a substantial team with a critical mass of researchers and expertise needed to address key biopharma research challenges, contributing to industry outcomes and positioning Australian Biopharma manufacturing to benefit from Industry 4.0.
The Hub is a collaborative program of significant scope and scale funded through the Australian Research Council Industrial Transformation Research Hub scheme with contributions from all partners of more than $18 M (cash and in kind).
It draws together expertise from The University of Melbourne, University of Technology Sydney and RMIT University, together with partner organisations CSL Innovation, Pall Australia and Patheon Biologics Australia. Three Other Organisations (Yokogawa Insilico Biotechnology, Mass Dynamics and Sartorius) and three leading international universities (University of Tartu, Estonia; Utrecht University, Netherlands; The University of Nottingham, United Kingdom) are also participants of the Hub.
This forms a substantial team with a critical mass of researchers and expertise needed to address key biopharma research challenges, contributing to industry outcomes and positioning Australian Biopharma manufacturing to benefit from Industry 4.0.